Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,234
datasets available to search
ShareScore release 0.9.0
Dataset results
2,234 results for “Paclitaxel”
Evaluation of transcription factor knockout impact on paclitaxel response for Triple Negative Breast Cancer
<div>Data and code related to Zenodo repository: 10.5281/zenodo.11238552</div> <div> </div> <div>Two experimental formats included:</div> <div>'fixed' prefix: data from terminal time point of siRNA screen applied to HCC1143, HCC1806, and MDA-MB-468 Triple Negative Breast Cancer cell lines.</div> <div>'live' prefix: data from live-cell imaging of cell cycle reporter (HDHB-mClover/NLS-mCherry) HCC1143 Triple Negative Breast Cancer cell line.</div> <div>Note: 'live' level 1 data is available upon request (heiserl@ohsu.edu, calistri@ohsu.edu).</div> <div> </div> <div>Experimental goal:</div> <div>Evaluate whether siRNA knockdown of transcription factors elevated during paclitaxel response impact cell count, cell morphology or cycling dynamics.</div> <div> </div> <div>Methods:</div> <div>siRNA Knockdown: Cells were plated in 90ul of serum free media per well of a 96 well plate. 24 hours later, siRNA knockdown mixture was prepared using a cell-line optimized concentration of Lipofectamine RNAiMAX (cat 13778075-075, Invitrogen) and siRNA (Horizon Discovery ON-TARGETplus) following RNAiMAX recommended protocol. The final concentration of siRNA per well was 1pmol and the final volume of RNAiMAX per well was 75nL for HCC1143, and 37.5nL for HCC1806 or MDA-MB-468 in 100uL of cell containing volume. 24 hours after siRNA transfection cells were treated with an addition of 100uL complete media containing either DMSO vehicle control or paclitaxel. </div> <div> </div> <div>Fixed-cell assays: Cells were plated at 3000 cells in 100ul of complete media per well in a 96 well plate (#08-772-225, FisherScientific). After 24 hours, an additional 100ul of either vehicle (0.1% DMSO) or paclitaxel containing complete media was added. After 72 hours cells were fixed with 4% Formaldehyde (#28908, ThermoFisher Scientific) for 15 minutes at room temperature, then permeabilized with 0.3% Triton X-100 (#X100-100ML, Sigma Aldrich) for 10 minutes at room temperature, then washed twice with PBS. Fixed cells were then stained with 0.5ug/mL DAPI (4083S, Cell Signaling Technology) in PBS for 15 minutes at room temperature. Following DAPI staining, wells were washed once with PBS, then stained with 1:20,000 HCS CellMask Green in PBS (H32714, Invitrogen) for 15 minutes at room temperature. Wells were washed twice with room temperature PBS and then 4 fields of view per well imaged on an InCell 6000 (GE Healthcare). Images were segmented with two custom Cellpose models to segment the nucleus (using parameters: diameter = 50, chan = DAPI, chan2 = Cellmask Orange) and cytoplasm (using parameters: diameter = 90, chan = Cellmask Orange, chan2 = DAPI). Image quantification was performed in R (v4.3.1) using EBImage (v4.42.0), and cells were annotated based on the number of distinct nuclei segmented within each cytoplasmic mask. </div> <div> </div> <div>HDHB reporter live-cell assays: siRNA knockdown and drug treatment was performed as described above, and then the plate was loaded on an Incucyte S3 (Sartorious) and cells imaged every 15 minutes for 72 hours post drug treatment. At each timepoint 4 fields of view were captured at 20x magnificantion in each well using the phase, red and green channels. A cytoplasmic mask was computed from the mean of normalized red/green channel (cellpose parameters: diameter = 57, chan = mean(normalized(red), normalized(green)), and a nuclear mask was computed from the red channel (cellpose parameters: diameter = 30, chan = DAPI) using custom trained Cellpose models. Image quantification was performed in R (v4.3.1) using EBImage (v4.42.0). An additional perinuclear ring mask was computed as the 11 pixel dilation from the nuclear mask, but still bound by the cytoplasmic mask. To determine mClover localization thresholds for cell cycle assignment, 250 cell images were randomly selected and manually assigned to the G1, S/G2 or M cell cycle state based on mClover localization. The mClover intensity ratios were then used to determine thresholds for automated cell cycle phase calling which was applied to the rest of the data set (Supplemental Figure 5A). Mononuclear cells with a Perinuclear:Nuclear mean intensity ratio greater than 0.8 and Nuclear:Cytoplasmic total intensity less than 0.5 were assigned to the S/G2 phase. Mononuclear and Multinuclear cells with a Nuclear:Cytoplasmic total intensity ratio greater than 0.8 and Perinuclear:Nuclear mean intensity ratio less than 0.8 were assigned to the ‘M’ phase. The remainder of mononuclear cells were assigned ‘G1’, and the remainder of multinucleated cells were assigned ‘Multinucleated’. </div> <div> </div> <div>Included files:</div> <div>fixed_level_1-plate_#.zip : Six .zip archives containing the raw images (DAPI/CellMask/Brightfield) from fixed-cell experiments.</div> <div>plate 1: HCC1143 cells treated with plate A schema</div> <div>plate 2: HCC1143 cells treated with plate B schema</div> <div>plate 3: HCC1806 cells treated with plate A schema</div> <div>plate 4: HCC1806 cells treated with plate B schema</div> <div>plate 5: MDA-MB-468 cells treated with plate A schema</div> <div>plate 6: MDA-MB-468 cells treated with plate B schema</div> <div>fixed_level_2: Data quantified from cellpose masks at the single-nuclei level (redundant cytoplasm information)</div> <div>fixed_level_3: Data from 'fixed_level_2.csv' collapsed to the single cell level, including staining intensity and aggregate nuclear information</div> <div>fixed_incell_to_cellpose.rmd: R markdown code for converting original incell files (fixed_level_1) to RGB images for cellpose segmentation</div> <div>fixed_image_quantification.rmd: R markdown code for quantifying images using cellpose segmentation masks and original images (fixed_level_1)</div> <div>fixed_cellpose_models.zip: Archive including cellpose models used for fixed experiment</div> <div>live_level_2: Data quantified from cellpose masks at the single-nuclei level (redundant cytoplasm information)</div> <div>live_level_3: Data from 'live_level_2.csv' collapsed to the single cell level, including staining intensity and aggregate nuclear information</div> <div>live_level_4: Data from 'live_level_3.csv' collapsed to the single condition level summarizing the number, multinucleation status and phase of cells at each time point.</div> <div>live_image_quantification.rmd: R markdown code for quantifying images using cellpose segmentation masks and original images (live_level_1).</div> <div>l ive_incu_archive2rgb.rmd: R markdown code for converting incucyte archive formatted data into RGB images, where the blue channel is the arithmetic mean of the min-max (0-1) normalized red and green channels.</div> <div>live_cellpose_models.zip: Archive including cellpose models used for live experiment.</div> <div> </div> <div> </div>
Impact of paclitaxel treatment on the Triple Negative Breast Cancer Cell line HCC1143
<div>Data and code related to Zenodo repository: 10.5281/zenodo.11237850</div> <div> </div> <div>Experimental goal:</div> <div>Evaluate the impact of escalating paclitaxel dose on cell count, nuclear morphology and cellular outcome.</div> <div> </div> <div>Methods:</div> <div>Cells were plated at 3000 cells in 100ul of complete media per well in a 96 well plate (#08-772-225, FisherScientific). After 24 hours, an additional 100ul of either vehicle (0.1% DMSO) or paclitaxel containing complete media was added. After 72 hours cells were fixed with 4% Formaldehyde (#28908, ThermoFisher Scientific) for 15 minutes at room temperature, then permeabilized with 0.3% Triton X-100 (#X100-100ML, Sigma Aldrich) for 10 minutes at room temperature, then washed twice with PBS. Fixed cells were blocked with 1% BSA (A7906-100G, Millipore Sigma) in PBS for 1 hour at room temperature and then stained overnight with 1:100 anti-CDKN2A/p16INK4A+CDKN2B/p15INK4B-AF644 (#ab199756, Abcam), and 1:100 anti-cPARP-AF647 (#6987S, Cell Signaling Technology) or 1:500 anti-TUBB3-AF647 (#ab190575, Abcam) overnight at 4C. Each well was washed twice with room temp PBS then stained with 0.5ug/mL DAPI (4083S, Cell Signaling Technology) in PBS for 15 minutes at room temperature. Following DAPI staining, wells were washed once with PBS, then stained with 1:20,000 HCS CellMask in PBS (Orange: #H32713, Green: #H32714, Invitrogen) for 15 minutes at room temperature. Wells were washed twice with room temperature PBS and then 4 fields of view per well imaged on an InCell 6000 (GE Healthcare). Images were segmented with two custom Cellpose models to segment the nucleus (using parameters: diameter = 45, chan = DAPI, chan2 = Cellmask Orange) and cytoplasm (using parameters: diameter = 90, chan = Cellmask Orange, chan2 = DAPI). Image quantification was performed in R (v4.3.1) using EBImage (v4.42.0), and cells were annotated based on the number of distinct nuclei segmented within each cytoplasmic mask. </div> <div> </div> <div>Included files:</div> <div>row_#_level_1.zip : 6 zip file containing original images from InCell 6000, one zip per row</div> <div>level_2.csv : Data quantified to the nuclear level (cytoplasmic quantification is duplicates across multiplet nuclei)</div> <div>level_3.csv: Data quantified at the cellular level including number of nuclei and stain intensities for segmented compartments</div> <div>platemap.csv: Description of each well from the stained plate</div> <div>cellpose_modelz.zip: Zip file containing the two CellPose models used for segmentation</div> <div>image_quantification.rmd : R markdown file containing code for extracting and quantifying image intensities using the raw images (level_1) and segmentation masks created from cellpose.</div>
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
ClinicalTrials.gov study NCT00272987. IPD Sharing: YES. Countries: 2. Publications: 1.
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Can
ClinicalTrials.gov study NCT02163694. IPD Sharing: YES. Countries: 37. Publications: 5.
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy
ClinicalTrials.gov study NCT01852292. IPD Sharing: UNDECIDED. Countries: 18. Publications: 2.
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
ClinicalTrials.gov study NCT00709761. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
ClinicalTrials.gov study NCT01816594. IPD Sharing: YES. Countries: 4. Publications: 1.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00876395. IPD Sharing: UNDECIDED. Countries: 28. Publications: 3.
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
ClinicalTrials.gov study NCT04472429. IPD Sharing: YES. Countries: 13. Publications: 2.
Dataset of A Review on the Efficacy, and Safety of nab-paclitaxel with Gemcitabine in Combination with other Drugs
<p>Dataset of A Review on the Efficacy, and Safety of nab-paclitaxel with Gemcitabine in Combination with other Drugs as New Therapeutic Strategies in Pancreatic Cancer</p> <p><strong>Table 1.</strong> Patient characteristics.</p> <p><strong>Table 2.</strong> The Joanna Briggs Institute Critical Appraisal Checklist</p> <p><strong>Table 3.</strong> The Joanna Briggs Institute critical appraisal checklist for quasi-experimental studies (non-randomized experimental studies)</p> <p><strong>Table 4</strong>. Comparison of response to treatment</p> <p><strong>Table 5.</strong> Summary of all grades Adverse Events (AE) in treatments that include placebo</p> <p><strong>Table 6.</strong> Summary of all grades Adverse Events (AE) in treatments that include no placebo</p>
RPE-1 GFP-H2B iCas9 cells undergoing paclitaxel-induced mitotic arrest
<p>Phasefocus LiveCyte video showing RPE-1 GFP-H2B iCas9 cells undergoing paclitaxel-induced mitotic arrest. Cells were treated with 1 μg/mL doxycycline for 96 hours to induce Cas9 expression and were imaged every 9 minutes for 48 hours at 20x magnification. From 3:17 cells start entering mitosis as indicated by their rounding up into a ball; from 12:44 mitotic cells begin to either slip from mitosis as indicated by rounded mitotic cells flattening or undergoing mitotic cell death as indicated by the presence of propidium iodide (red).</p>
Wikidata Dump drug_paclitaxel
<p>RDF dump of wikidata produced with <a href="//wdumps.toolforge.org/">wdumper</a>.</p><p><br><a href="//wdumps.toolforge.org/dump/2813">View on wdumper</a></p><p><b>entity count<b>: 0, <b>statement count</b>: 0, <b>triple count</b>: 0</b></b></p>
Wikidata Dump drug_paclitaxel
<p>RDF dump of wikidata produced with <a href="//wdumps.toolforge.org/">wdumper</a>.</p><p><br><a href="//wdumps.toolforge.org/dump/2813">View on wdumper</a></p><p><b>entity count<b>: 0, <b>statement count</b>: 0, <b>triple count</b>: 0</b></b></p>
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
ClinicalTrials.gov study NCT02430311. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
ClinicalTrials.gov study NCT00003377. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov study NCT03943667. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative B
ClinicalTrials.gov study NCT02322814. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negati
ClinicalTrials.gov study NCT01881230. IPD Sharing: Not stated. Countries: 12. Publications: 2.
A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer
ClinicalTrials.gov study NCT00937560. IPD Sharing: Not stated. Countries: 9. Publications: 1.
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-
ClinicalTrials.gov study NCT02366143. IPD Sharing: Not stated. Countries: 26. Publications: 9.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.